Imagine your arteries are like pipes that get clogged with fatty gunk and rust, eventually cutting off water to a garden. This technology acts like a smart cleaner that finds only the rusted spots and scrubs them clean while preventing new clogs from forming. It stops the inflammation and blood clots that usually lead to doctors having to remove a limb.
Patients with advanced peripheral arterial occlusive disease face high mortality and amputation rates because current therapies fail to safely and effectively target the specific sites of inflammation and clotting in the lower limbs.
A vascular injury-targeting drug (APAC) and the associated clinical manufacturing process, including validated zirconium-labelling methods.
If you are a drug developer dealing with the high failure rate of systemic treatments for blood flow—this project developed a targeted drug (APAC) that focuses specifically on sick arteries to reduce inflammation and clotting.
If you are a clinic dealing with high rates of limb amputation in patients with critical limb ischemia—this project developed a local treatment that targets atherosclerotic sites to improve patient survival and limb salvage.
If you are a biotech firm dealing with the challenge of delivering medicine only to injured vessel walls—this project developed a vascular injury-targeting product that provides long-term antithrombotic effects.
Based on available project data, specific pricing or cost-per-dose information is not provided.
The project has successfully manufactured clinical batches and developed an improved formulation currently in long-term stability studies, indicating a move toward scalable production.
Based on available project data, the project is led by Aplagon OY, but specific patent numbers or licensing terms are not listed.
The project has received regulatory approval to enter clinical studies and has had two clinical batches released by a Qualified Person (QP) in Europe.
The project period runs from 2022-09-01 to 2025-02-28, focusing on showing safety and preliminary efficacy as a value inflection point.
The project is managed by a single SME, Aplagon OY from Finland. This 100% industry-led structure suggests a highly focused commercial drive, as there are no university or research partners slowing down the transition from lab to clinic.
Contact Aplagon OY in Finland regarding clinical trial results for APAC.
Contact us to find licensing opportunities for targeted vascular therapies.
